Understanding how crystal structures reflect the range of possible G protein-coupled receptor (GPCR) states is critical for rational drug discovery (RDD). Combining computational simulations with mutagenesis and binding studies, we find that the structure of the dopamine D2 receptor (D2R)/risperidone complex captures an inactive receptor conformation that accommodates some but not all antagonist scaffolds. Indeed, we find that eticlopride binds D2R in a configuration very similar to that seen in the D3R structure, in a pose that is incompatible with the D2R/risperidone structure. Moreover, our simulations reveal that extracellular loops 1 and 2 (EL1 and EL2) are highly dynamic, with spontaneous transitions of EL2 from the helical conformation in the D2R/risperidone structure to an extended conformation similar to that in the D3R/eticlopride structure. Our results highlight previously unappreciated conformational diversity and dynamics in the inactive state of a GPCR with potential functional implications. These findings are also of paramount importance for RDD as limiting a virtual screen to one state will miss relevant ligands.
INTRODUCTION
G protein-coupled receptors (GPCRs) are important therapeutic targets for numerous human diseases. Our understanding of GPCR functional mechanisms has evolved from a simple demarcation of single active and inactive states to the appreciation and detection of multiple active states responsible for partial or biased agonism [1] [2] [3] . High-resolution crystal structures of these proteins are vital for structure-based (rational) drug discovery (RDD) efforts designed to tailor selectivity and efficacy 4, 5 . Indeed, a current focus of the field is on developing functionally biased ligands [6] [7] [8] that couple preferentially to a particular effector pathway. Less attention has been dedicated to the possibility that there may be multiple inactive states, and that different antagonist scaffolds might lead to different receptor conformations. Such a possibility could have major impact on RDD for antagonists, since a crystal structure of a receptor with a particular ligand bound might represent an invalid docking target for an antagonist that binds in a different pose to a different inactive conformation. Although substantial differences in antagonist binding mode and position of the binding pockets have been revealed between different aminergic receptors, no differences in conformation has been detected for the inactive state of any individual aminergic receptor 5 .
In particular, although a number of antagonists from different scaffolds have been cocrystallized with β2 adrenergic receptor, the conformational differences among these crystal structures are minimal 5 .
Curiously, the structures of the highly homologous dopamine D2 and D3 receptors (D2R and D3R) in the inactive states revealed quite substantial differences on the extracellular side of the transmembrane domain when bound with antagonists from different scaffolds 9, 10 . Specifically, the D3R structure is in complex with eticlopride, a substituted benzamide (PDB: 3PBL) 9 , while the D2R structure is bound with risperidone, a benzisoxazole derivative (PDB: 6CM4) 10 . The binding poses of the two ligands differ substantially. The risperidone is oriented relatively perpendicular to the membrane plane with its benzisoxazole ring penetrating into a hydrophobic pocket beneath the orthosteric binding site (OBS) of D2R; in contrast, eticlopride is oriented relatively parallel to the 4 membrane plane contacting the extracellular portion of TM5 in D3R that risperidone does not touch in D2R 10, 11 . Nemonapride, another substituted benzamide, binds in the OBS of the slightly divergent D4R (PDB: 5WIV) 12 in a manner very similar to that of eticlopride in the D3R 11 . The benzisoxazole moiety of risperidone is enclosed by 8 residues in D2R that are identical among all D2-like receptors (i.e., D2R, D3R, and D4R): Cys118 3.36 (superscripts denote Ballesteros-Weinstein numbering 13 ), Thr119 3.37 , Ile122 3.40 , Ser197 5.46 , Phe198 5.47 , Phe382 6.44 , Trp386 6.48 , and Phe390 6.52 .
Notably, three of these residues on the intracellular side of the OBS, Ile122 3.40 , Phe198 5.47 , Phe382 6.44 , accommodate the F-substitution at the tip of the benzisoxazole ring in a small cavity (termed herein as the Ile 3.40 sub-pocket) (Fig. 1a) . Interestingly, this Ile 3.40 sub-pocket is collapsed in both the D3R and D4R structures 11 ( Fig. 1b,c) . We noted that this collapse is associated with rotation of the sidechain of Cys 3.36 : In the D2R/risperidone structure, the sidechain of Cys 3.36 faces the OBS, whereas it rotates downwards to partially fill the Ile 3.40 sub-pocket in the D3R/eticlopride and D4R/nemonapride structures.
Importantly, the co-crystalized ligands (risperidone, eticlopride, and nemonapride) display little subtype selectivity across D2-like receptors 9, 12, 14, 15 (also see PDSP database 16 ). Given the high homology among D2-like receptors, especially between D2R and D3R in and near the OBS, we hypothesized that the drastic conformational differences between the structures of these receptors in the inactive state are mostly due to the different binding poses of antagonists of different scaffolds and not to inherent differences between the two receptors. To test this hypothesis, we carried out extensive molecular dynamics (MD) simulations of D2R in complex with non-selective antagonists of different scaffolds to characterize the plasticity of the OBS and the extracellular loop dynamics in the inactive conformational state.
RESULTS
In the D2R structure, Ile122 3.40 , Leu375 6.37 , and Leu379 6.41 were mutated to Ala to thermostabilize the receptor for crystallography. We reverted these thermostabilizing mutations back to their WT residues and established WT D2R models in complex with selected ligands (see Methods, Supplementary Fig. 1 and Supplementary Table 1) .
Spiperone but not eticlopride extends into the Ile 3.40 sub-pocket
In our MD simulations of the WT D2R/risperidone complex, we observed that risperidone stably maintains the binding pose captured in the crystal structure, even without the thermostabilizing mutations (Fig. 1d) . Thus, the I122 3.40 A mutation has minimal impact on the binding pose of risperidone. Interestingly in the simulations of the D2R model in complex with spiperone, a butyrophenone derivative, the F-substitution on the butyrophenone ring similarly occupies the Ile 3.40 sub-pocket as risperidone (Fig. 1e) . Note that the F-substitutions in risperidone and spiperone are located at similar distances to the protonated N atoms that interact with Asp 3.32 (measured by the number of carbon atoms between them, Supplementary Fig. 1 ) and these two ligands appear to be optimized to occupy the Ile 3.40 sub-pocket.
In contrast, in our simulations of the D2R/eticlopride complex, the eticlopride pose revealed in the D3R structure (PDB: 3PBL) is stable throughout the simulations and does not protrude into the Ile 3.40 sub-pocket (Fig. 1f) . Consistent with the difference in the crystal structures noted above (Fig. 1a,b) , when risperidone and spiperone occupy the Ile 3.40 sub-pocket, the sidechain of Cys118 3.36 rotates away with its χ1 rotamer in gauche-, while in the presence of the bound eticlopride, this rotamer is in trans (Supplementary Fig. 2 ). sub-pocket but have no effect on eticlopride binding, while the smaller Ala should not affect the binding of spiperone or risperidone. Consistent with this hypothesis, compared to WT, the I122W mutation significantly decreased the binding affinities of risperidone and spiperone but had no effect on that of eticlopride. In contrast, the I122A mutation did not affect the affinities of spiperone or risperidone but caused a 3-fold increase in the affinity of eticlopride. This is consistent with our simulation results that show the I122 3.40 A mutation has minimal impact on risperidone binding. , and we have found that the I122A mutation renders the receptor non-functional 10, 18 . Thus, the I122A mutation may promote an inactive conformation of D2R that favors eticlopride binding but has no effect on the binding of risperidone or spiperone. This is consistent with our proposal that different antagonist scaffolds may favor distinct inactive conformations of D2R.
We have previously shown that the binding of structurally distinct antagonists to the OBS is differentially modulated by the Na + bound in a conserved allosteric binding pocket coordinated by Asp 2.50 and Ser 3.39 . While spiperone binding was insensitive to the presence of Na + , the affinities of eticlopride and sulpiride were increased and the affinity of zotepine was decreased 19 . In our current simulations, the occupancy of the Ile 3.40 sub-pocket by both spiperone and risperidone was unaffected by the presence or absence of bound Na + ( Supplementary Fig. 2 ). Note that Ser Fig. 2 ). Intriguingly, in the recently reported crystal structure of the serotonin 2A receptor (5-HT2AR) in complex with zotepine (PDB: 6A94) 20 , the benzothiepin moiety of zotepine also occupies the Ile 3.40 sub-pocket, but this results in noticeable differences in the nearby residues compared to the 5-HT2AR/risperidone structure (PDB: 6A93) 20 . Specifically, the sidechain of the thermostabilizing mutation S162 would clash with the bound eticlopride ( Fig. 2b ). These findings further support our inference that these differences between the D2R and D3R inactive structures are largely due to the different scaffolds of the non-selective ligands bound.
The extracellular loop 2 (EL2) of D2R/risperidone can spontaneously unwind.
In addition to these differences in the transmembrane segments surrounding the OBS, there are also substantial differences in the configuration of EL2 in the D2R and D3R structures. EL2
(residues 173 to 186) between TM4 and TM5 is connected to TM3 via a disulfide bond formed between Cys182 EL2.50 (see Methods and Supplementary Fig. 3 for the indices of EL1 and EL2 residues) and Cys107 3.25 . The conformation of EL2, the sequence of which is not conserved among aminergic GPCRs, is expected to be dynamic. Indeed, in the D2R/risperidone structure, 3b, step iii).
In the D3R structure, the aligned residue for Asp108 3.26 of D2R is conserved as Asp104 3.26 ; its sidechain forms an interaction not with Ile182 EL2.51 but rather with the sidechain of Asn173 EL2.39 , which is also conserved in D2R as Asn175 EL2.39 . In the D4R, the aligned two residues (Asp109 3.26 and Asn175 EL2.39 ) are conserved as well, their sidechains are only 4.3 Å away in the D4R structure, slightly larger than 3.2 Å in the D3R structure. Even though these residues are conserved in D2R, the interaction in D3R (and potentially in D4R), between Asp
, is not present in the D2R structure in which the aligned Asn175 EL2.39 faces lipid (Fig. 3a) . However, in a few of our long D2R
simulations, Asn175 EL2.39 gradually moves inwards and approaches Asp108 3.26 ( Fig. 3b, step iv) .
At this point, the EL2 conformation of D2R is highly similar to that of D3R (Fig. 3c) , suggesting that EL2 is dynamic and can exist in both conformations.
Both EL2 conformation and ligand scaffold affect the EL1 conformation.
We have previously shown that the divergence in both the length and number of charged residues in EL1 among D2R, D3R, and D4R is responsible for the selectivity of more extended ligands 21, 22 . Another striking difference in the D2R, D3R, and D4R structures is the position of the conserved Trp EL1.50 in EL1. Trp100 EL1.50 is in a much more inward position in the D2R structure, making a direct contact with the bound risperidone (Fig. 4a) , Trp101 EL1.50 in D4R interacts with the bound nemonapride that has an extended structure, whereas Trp96 EL1.50 in D3R is not in contact with eticlopride (Fig. 4b) . Thus, we asked whether these distinct positions of Trp EL1.50 are due to the divergence in EL1 among these receptors 21 or due to the multiple inactive conformations that accommodate the binding of non-selective ligands of divergent scaffolds.
In the D2R/risperidone simulations, we found that when residues 182 , which is flexible as well but can adopt a position that is even further away from the OBS than that of Trp96 EL1.50 in the D3R structure ( Supplementary Fig. 4 ).
In contrast, when EL2 is in an extended conformation like that in D3R, it restricts the flexibility of Trp100 EL1.50 (Supplementary Movie 3). This trend is consistent with the D3R/eticlopride simulations in which we do not observe any significant rearrangement of Trp96 EL1.50 (Fig. 4d,e,f) .
Thus, we infer that the distinct conformation of Trp100 EL1.50 in the D2R structure is a combined effect of the helical EL2 conformation and the favored interaction that Trp100 EL1.50 can form with bound risperidone in the crystal structure, the latter of which however, has a minimal influence on the binding affinity of risperidone 10 , consistent with the unstable interaction between risperidone and Trp100 EL1.50 in our simulations (Fig. 4, Supplementary Movie 2) . The mutation of this residue to alanine, leucine or phenylalanine did, however, cause substantial increases in both the association and dissociation rate of risperidone 10 .
Thus, it appears that the conformation of EL2
influences the dynamics of Trp100 EL1.50 , which in turn controls ligand access and egress to and from the OBS. Both the dissociation and association rates of D2R antagonists used as antipsychotics have been proposed to determine their propensity to cause extrapyramidal sideeffects and hyperprolactinaemia 24 . Understanding the relationship between the distinct inactive D2R conformations stabilized by different antagonist scaffolds and these kinetic parameters will likely be important to facilitate the design of D2R antagonists with an optimal kinetic profile that minimizes the risk of side effects.
EL2 and EL1 dynamics.
Next, we evaluated the tendency of the EL2 helix to unwind in each of the simulated D2R complexes, by measuring the stability of the backbone H-bond between Ile183 EL2.51 and
Asn186
EL2.54
, a key stabilizing force of the helix (Fig. 5a) (Fig. 5c,d , Supplementary Movies 1 and 3) . Note in the D3R/eticlopride simulations, the aligned residues Ser182 EL2.51 and Asn185 EL2.54 does not form such a H-bond, and EL2 is always in an extended conformation ( Fig. 5b-d ). This trend of EL2 to transition towards the extended conformation is also present in our simulations of D2R in complex with a partial agonist, aripiprazole, whereas EL2 in the D3R complexes with partial agonists (R22 and S22) remains in the extended conformation (Supplementary Table 1 and Supplementary Fig. 5 ). Interestingly, -Asn185 EL2.54 interaction can sporadically form in the D3R/R22 simulationsboth raise a possibility that the extended conformation of D3R EL2 may transition to a helical conformation. In addition, while differences in the probabilities of unwinding for each D2R complex in Fig. 5 were not drastic, this may be a result of insufficient sampling and cannot exclude the possibility that different ligands may favor particular conformational equilibrium of EL2.
In the fully extended EL2 conformation in which Ile183 EL2.51 rotates to face the extracellular vestibule, Ile183 EL2.51 makes a direct contact with the bound risperidone, whereas Trp100 contacting risperidone aligns to Ile183 EL2.51 of D2R, whereas the conserved Trp141 EL1.50 does not interact with risperidone in the 5-HT2AR. It is tempting to speculate the EL2 and EL1 dynamics we observe in the D2R/risperidone simulations represents a more comprehensive picture, as the divergent interactions shown in the extracellular loops of the 5-HT2AR/risperidone and D2R/risperidone structures may not result from differences in recognizing the ligand but rather two different static snapshots due a variety of differences in the crystallographic conditions (Note risperidone has similarly high affinities for both D2R and 5HT2AR 10, 20 ). Interestingly, in one of our long MD trajectories of the D2R/risperidone complex, EL2 evolved into a conformation that has a helical N-terminal portion and an extended C-terminal portion (Supplementary Movie 4 and Supplementary Fig. 6 ). This conformation is not observed in either of the D2R/risperidone and 13 D3R/eticlopride structures but is similar to that of the 5-HT2AR/risperidone structure, further demonstrating the dynamics of this loop region ( Supplementary Fig. 6 ).
Thus, the plasticity of the OBS and the dynamics of the extracellular loops appear to be two associated modules in ligand recognition. To the extent of our simulations, we did not detect strong ligand-dependent bias in the EL2 dynamics as we did for the OBS. However, when EL2 is helical, the EL1 dynamics are sensitive to the bound ligand (compare Fig. 4 and Supplementary   Fig. 4) ; when EL2 is extended, it restricts the EL1 dynamics (Fig. 4 ). Fig. 7 ). Indeed, we observed spontaneous transitions from the C-terminal helical EL2 conformation to a C-terminal extended conformation in our D2R simulations, which suggests that the EL2 conformation of D2R exists in an ensemble of structured and unwound conformations, with substantial occupation of the configuration found in D3R. Such dynamics of EL2 would explain why the binding of non-selective ligands, such as risperidone or eticlopride, can result in drastically different conformations between the D2R and D3R structures near EL2, which are not related to the divergence of the receptors. Thus, the D2R EL2 appears to have quite dramatic dynamics that are not captured by the crystal structure.
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DISCUSSION
In marked contrast to the obvious trend toward unwinding of EL2 in all our simulated D2R complexes, in our recent simulations of MhsT, a transporter protein with a region found by crystallography to alternate between helical and unwound conformations 29 , we failed to observe any spontaneous unwinding over a similar simulation timescale (with the longest simulations being ~5-6 µs) when the region was started from the helical conformation 30, 31 . This suggests that the C-terminal helical conformation of EL2 represents a higher energy state than the extended conformation, which allows for observation of the transitions in a simulation timescale not usually adequate to sample folding/unfolding events 32 .
Taken together, our findings reveal that both the plasticity of the transmembrane domain in accommodating different scaffolds and the dynamics of EL2 and EL1 are important considerations in RDD targeting the inactive conformation of D2R. More extensive simulations and additional crystal structures bound with ligands from different scaffolds will help to fully reveal the correlations between these two modules.
METHODS
Residue indices in EL1 and EL2
Based on a systematic analysis of aminergic receptors, we found a Trp in the middle of EL1 and the disulfide-bonded Cys in the middle of EL2 are the most conserved residues in each segment, and defined their residue indices as EL1.50 and EL2.50, respectively 5 , In this study, for the convenience of comparisons among D2R, D3R, and D4R, and 5-HT2AR, based on the alignments of EL1 And EL2 shown in Supplementary Fig. 3 , we index the EL1 and EL2 residues of each receptor in the same way as the Ballesteros-Weinstein numbering, e.g., the residues before and after the EL2.50 are EL2.49 and EL2.51, respectively. Note the indices for the shorter sequences are not be consecutive, given the gaps in the alignment.
Molecular modeling and docking
The D2R models in this study are based on the corrected crystal structure of D2R bound to risperidone (PDB: 6CM4) 10 . We omitted T4 Lysozyme fused into intracellular loop 3. Three thermostabilizing mutations (Ile122 3.40 A, L375 6.37 A, and L379 6.41 A) were reverted to their WT residues. The missing N terminus in the crystal structure was built de novo using Rosetta
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, and then integrated with the rest of the D2R model using Modeller 34 . Using Modeller, we also extended two helical turns at the TM5 C terminus and threes residues at the TM6 N terminus of the structure and connected these two ends with a 9 Gly loop, similar to our experimentally validated treatment of D3R models 35 . The position of the Na + bound in the canonical Na + binding site near the negatively charged Asp 2.50 was acquired by superimposing the Na + bound structure of adenosine A2A receptor 36 to our D2R models. . The system charges were neutralized, and 150 mM NaCl was added. Each system was first minimized and then equilibrated with restraints on the ligand heavy atoms and protein backbone atoms, followed by production runs in an isothermal-isobaric (NPT) ensemble at 310 K and 1 atom with all atoms unrestrained, as described previously 19, 35 .
We used Langevin constant pressure and temperature dynamical system 45 to maintain the pressure and the temperature, on an anisotropic flexible periodic cell with a constant-ratio constraint applied on the lipid bilayer in the X-Y plane. For each condition, we collected multiple trajectories, the aggregated simulation length is ~340 μs (Table S1 ).
While the majority of our D2R simulations in this study used the OPLS3 force field, to compare with the D3R simulations using CHARMM36 that have been continued from the previously reported shorter trajectories 19, 35 , we carried out the D2R/eticlopride simulations using both the OPLS3 and CHARMM36 force fields (see Table S1 ). We did not observe significant differences and pooled their results together for the analysis.
Conformational analysis
Distances and dihedral angles of MD simulation results were calculated with MDTraj (version 1.8.2) 46 in combination with in-house Python scripts.
To characterize the structural changes in the receptor upon ligand binding, we quantified differences of structural elements between the D2R/eticlopride and D2R/risperidone conditions (using last 600 ns from a representative trajectory for each condition), by applying the previously described pairwise interaction analyzer for GPCR (PIA-GPCR) 35 . The subsegments on the extracellular side of D2R were defined as following: TM1e (the extracellular subsegment (e) of TM1, residues 31-38), TM2e (residues 92-96), TM3e (residues 104-113), TM4e (residues 166-172), TM5e (residues 187-195), TM6e (residues 364-369), and TM7e (residues 376-382).
For the PIA-GPCR analysis and the distance analysis in Fig. 4 , we used the set of ligand binding residues previously identified by our systematic analysis of GPCR structures. 
Markov State Model (MSM) analysis
The MSM analysis was performed using the pyEMMA program (version 2.5.5) 47 . To characterize the dynamics of EL2 of D2R, specifically the transitions between helical and extended conformations of its C-terminal portion, we focused on a key hydrogen bond formed in the helical conformation between the backbone carbonyl group of Ile183 and the backbone amine group of Asn186. Thus, for each of the simulated conditions, the distance of Ile183-Asn186 (Ser182-Asn185 in D3R) was used as an input feature for the MSM analysis. We discretized this feature into two clusters -distances below and above 4 Å (i.e. EL2 forming a helical conformation and unwinding). Implied relaxation timescale (ITS) 48 for the transition between these clusters was obtained as a function of various lag times. Convergences of ITS for the MSMs for all conditions was achieved at a lag time of 300 ns ( Supplementary Fig. 8 ), which we further used to estimate Bayesian Markov models with 500 transition matrix samples 49 . The maximum likelihood transition matrix was used to calculate the transition and equilibrium probabilities (π) shown in Fig. 5 and Supplementary Fig. 5 . 
Data analysis
The concentration of ligand that inhibited half of the can be stabilized by interacting with the disulfide bond. The presentation and color scheme are similar to those in Supplementary Movie 1, except that the bound carbon atoms of the ligand eticlopride are colored in cyan.
Supplementary Movie 3.
A movie of a 3.6 µs D2R/eticlopride trajectory collected using the CHARMM36 force field shows another example of unwinding of EL2. Thus, considering the similar unwinding pathway as that in Movie S1 (Fig. 3) , the unwinding does not depend on the force field used in the simulations or the identity of the antagonist bound in the OBS. Note the sidechain of This is a novel EL2 conformation that has not been revealed by the D2R, D3R or D4R structures 46 but similar to those in the 5-HT2AR/risperidone, β2AR and β2AR structures ( Supplementary Fig.   S6 ). The presentation and color scheme are the same as those in Supplementary Movie 1.
